Tosatoxumab is under clinical development by Aridis Pharmaceuticals and currently in Phase III for Hospital Acquired Pneumonia (HAP). According to GlobalData, Phase III drugs for Hospital Acquired Pneumonia (HAP) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Tosatoxumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tosatoxumab overview
AR-301 (KBSA301) is under development for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (MSSA). KBSA301 is administered by intravenous route. It is developed based on MabIgX technology. It acts by targeting S. aureus alpha-toxin (alpha-hemolysin). It was also under development for sepsis and severe community-acquired pneumonia (CAP).
Aridis Pharmaceuticals overview
Aridis Pharmaceuticals (Aridis) is a biopharmaceutical company. The company develops novel, differentiated therapies for infectious diseases. Its pipeline products include AR-301 mAb, AR-105 mAb, AR-101 mAb, AR-501(Gallium Citrate), AR-401 mAb and AR-201 mAb. The company uses a disruptive platform technology to discover potent human monoclonal antibodies from patients. Its proprietary platform, MabIgXis used to discover potent therapeutic antibodies for any diseases and to generate an unrivaled product portfolio ofanti-infective mAbs. The company also works on macromolecular stabilization technology for increase the stability of vaccines. Aridis is headquartered in San Jose, California, the US
For a complete picture of Tosatoxumab’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - Tosatoxumab in Hospital Acquired Pneumonia (HAP)
Premium Insights
The gold standard of business intelligence.
